Castle Biosciences (CSTL) Investor Presentation - Slideshow

$13.8$22.8 $51.9$62.6 $94.1$137.0 2017 2018 2019 2020 2021 2022 58% 46% Near- to Mid-term Growth Mid- to Long-term Growth 11 1Due to COVID-19, cutaneous melanoma diagnoses were down 20% for 2020; 2 Cutaneous melanoma diagnoses were down 11% for 2021. Delivered strong year-over-year growth in revenue (met top end of guided range) and test report volume (total test reports delivered in 2022 were 44,419 up 58% over 2021) 1ADLT=Advanced Diagnostic Laboratory Test 5 Customer & Solution Centric Exceptional Emp ...